This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BSTC BioSpecifics Technologies (BSTC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioSpecifics Technologies Stock (NASDAQ:BSTC) 30 days 90 days 365 days Advanced Chart Get BSTC alerts:Sign Up Key Stats Today's Range$88.53▼$88.5350-Day Range$88.22▼$88.5352-Week Range$42.00▼$89.15VolumeN/AAverage Volume61,105 shsMarket Capitalization$650.25 millionP/E Ratio37.51Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. Read More Receive BSTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address BSTC Stock News HeadlinesSilicon Valley Technology NewsMarch 21, 2023 | bizjournals.comSee More Headlines BSTC Stock Analysis - Frequently Asked Questions How were BioSpecifics Technologies' earnings last quarter? BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.70. The biopharmaceutical company had revenue of $11.26 million for the quarter, compared to the consensus estimate of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a trailing twelve-month return on equity of 14.81%. What other stocks do shareholders of BioSpecifics Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioSpecifics Technologies investors own include Bristol Myers Squibb (BMY), AbbVie (ABBV), Biogen (BIIB), Pfizer (PFE), Intel (INTC), Johnson & Johnson (JNJ) and NVIDIA (NVDA). Company Calendar Last Earnings11/14/2020Today7/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BSTC CIK875622 Webwww.biospecifics.com Phone302-842-8450FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)$3.33 Trailing P/E Ratio37.51 Forward P/E Ratio61.91 P/E GrowthN/ANet Income$24.47 million Net Margins47.43% Pretax MarginN/A Return on Equity14.81% Return on Assets14.46% Debt Debt-to-Equity RatioN/A Current Ratio66.24 Quick Ratio66.24 Sales & Book Value Annual Sales$38.19 million Price / Sales17.03 Cash Flow$3.38 per share Price / Cash Flow26.18 Book Value$18.42 per share Price / Book4.81Miscellaneous Outstanding Shares7,345,000Free FloatN/AMarket Cap$650.25 million OptionableNot Optionable Beta0.24 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:BSTC) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSpecifics Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSpecifics Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.